Editorial

Adverse Event in Response to Aliskiren

Authors: Rajat Bhatt MD

Abstract

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Pietz GJ, Malesker MA, Stanislaw SG. Aliskiren-induced QT interval prolongation. South Med J 2009;2002:411–412.PietzGJ]]MaleskerMA]]StanislawSGAliskiren-induced QT interval prolongation.South Med J20092002411-4122. Product Information: TEKTURNA(R) Oral Tablets, Aliskiren Oral Tablets. East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2007.&NA;Product Information: TEKTURNA(R) Oral Tablets, Aliskiren Oral Tablets.East Hanover, NJNovartis Pharmaceuticals Corporation20073. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994;331:31–38.HohnloserSH]]WoosleyRLSotalol.N Engl J Med199433131-384. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.NaranjoCA]]BustoU]]SellersEM&etal;A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther198130239-245